Reconciling immunotherapy and autoimmunity: not for the faint of heart
Menée aux Etats-Unis à partir de données portant sur 87 patients atteints d'une polyarthrite rhumatoïde antérieure au diagnostic de cancer et sur 203 témoins, cette étude de cohorte rétrospective analyse l'association entre une utilisation d'inhibiteurs de points de contrôle immunitaire, la survenue d'événements indésirables et la mortalité
Immune checkpoint inhibitors, a class of immunotherapy, have revolutionised cancer therapy. Nearly half of all patients with metastatic cancer are eligible for immune checkpoint inhibitor treatment, and use for patients with early-stage cancers in the adjuvant setting is rapidly increasing. 1 Immune checkpoint inhibitors exert anti-tumour effects by blocking immune checkpoints, which typically downregulate T-cell responses and protect the body from inappropriate immune activation. Although immune checkpoint inhibitors have proven to be lifesaving for many individuals, they are known to cause immune-related adverse events (AEs) in most users
The Lancet Rheumatology , commentaire, 2022